DAWN
NASDAQDay One Biopharmaceuticals Inc.
Price$21.52+11.38 (+112.34%)
2026-01-162026-04-22
News · 26 weeks75-100%
2025-12-142026-06-07
Mix4190d
- SEC Filings17(41%)
- Insider13(32%)
- Other11(27%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Day One Biopharmaceuticals Inc.SCHEDULE 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
- SECSEC Form 15-12G filed by Day One Biopharmaceuticals Inc.15-12G - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
- INSIDERSEC Form 4 filed by Large owner Ai Day1 Llc4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Bender Jeremy returned 1,799,031 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERHead of Research and Dev. Vasconcelles Michael returned 4,397 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERCOO and CFO York Charles N Ii returned 312,025 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERGen Counsel & Secretary Dubow Adam returned 72,694 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERDirector Holles Natalie C. returned 57,310 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERDirector Ramasastry Saira returned 40,485 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERDirector Josey John A. returned 72,292 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERSEC Form 4 filed by Director Garland J. Scott (withholding tax)4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERSEC Form 4 filed by Director Dable Habib J to cover withholding tax4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERSEC Form 4 filed by Director Grossman William to satisfy withholding tax4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERSEC Form 4 filed by Director Nicholson Garry A to satisfy withholding tax4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- INSIDERChief Commercial Officer Merendino Lauren returned 60,157 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
- SECSEC Form 25-NSE filed by Day One Biopharmaceuticals Inc.25-NSE - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
- SECSEC Form S-8 POS filed by Day One Biopharmaceuticals Inc.S-8 POS - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
- SECSEC Form S-8 POS filed by Day One Biopharmaceuticals Inc.S-8 POS - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
- SECSEC Form S-8 POS filed by Day One Biopharmaceuticals Inc.S-8 POS - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
- SECSEC Form S-8 POS filed by Day One Biopharmaceuticals Inc.S-8 POS - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
- SECSEC Form S-8 POS filed by Day One Biopharmaceuticals Inc.S-8 POS - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
- SECSEC Form S-8 POS filed by Day One Biopharmaceuticals Inc.S-8 POS - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
- SECSEC Form POSASR filed by Day One Biopharmaceuticals Inc.POSASR - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
- SECSEC Form POSASR filed by Day One Biopharmaceuticals Inc.POSASR - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
- SECDay One Biopharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Leadership Update8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
DAWN FAQ
7 questionsWhat does Day One Biopharmaceuticals Inc. do?
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is...Where does DAWN stock trade?
Day One Biopharmaceuticals Inc. (DAWN) is listed on NASDAQ.What sector and industry is DAWN in?
Day One Biopharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Day One Biopharmaceuticals Inc. go public?
Day One Biopharmaceuticals Inc. (DAWN) completed its IPO in 2021.What are analysts saying about DAWN?
Day One Biopharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $2150.00 price target on 2026-03-10. Recent price targets range from $900.00 to $4000.00.What companies are similar to DAWN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DAWN side-by-side with any of them on Quantisnow.How can I track DAWN on Quantisnow?
Quantisnow aggregates Day One Biopharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DAWN to receive live email and push alerts on every new disclosure.